Concomitant KRAS and BRAF mutations in colorectal cancer

被引：38

作者：

Midthun, Lauren ^{[1
]}

Shaheen, Shagufta ^{[2
]}

Deisch, Jeremy ^{[3
]}

Senthil, Maheswari ^{[4
]}

Tsai, James ^{[5
]}

Hsueh, Chung-Tsen ^{[5
]}

机构：

[1] Loma Linda Univ, Dept Internal Med, Loma Linda, CA 92354 USA

[2] Stanford Med Ctr, Div Oncol, Stanford, CA USA

[3] Loma Linda Univ, Dept Pathol & Human Anat, Loma Linda, CA 92354 USA

[4] Loma Linda Univ, Dept Surg, Loma Linda, CA 92354 USA

[5] Loma Linda Univ, Div Med Oncol & Hematol, Dept Internal Med, 11175 Campus St,CSP 11015, Loma Linda, CA 92354 USA

来源：

JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2019年 / 10卷 / 03期

关键词：

BRAF; KRAS; colorectal cancer (CRC); SURVIVAL;

D O I：

10.21037/jgo.2019.01.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAP- kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations in both KRAS and BRAF genes have been identified in colorectal cancer (CRC). The clinical outcome of these patients remains undetermined. We present the clinical course of two patients with CRC harboring mutations at codon 12 of KRAS and BRAF non-V600E mutations. More research is needed to determine the clinical- pathological effect of these simultaneous mutations of KRAS and BRAF in CRC on disease course and treatment

引用

页码：577 / 581

页数：5

共 18 条

[1] BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies [J].

Clarke, Callisia N. ;

Kopetz, E. Scott .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (06) :660-667

[2] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[3] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[4]

Guglielmini PF, 2013, J CLIN ONCOL, V31

[5]

Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6

[6] Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer [J].

Jones, Jeremy C. ;

Renfro, Lindsay A. ;

Al-Shamsi, Humaid O. ;

Schrock, Alexa B. ;

Rankin, Andrew ;

Zhang, Ben Y. ;

Kasi, Pashtoon M. ;

Voss, Jesse S. ;

Leal, Alexis D. ;

Sun, James ;

Ross, Jeffrey ;

Ali, Siraj M. ;

Hubbard, Joleen M. ;

Kipp, Benjamin R. ;

McWilliams, Robert R. ;

Kopetz, Scott ;

Wolff, Robert A. ;

Grothey, Axel .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2624-+

[7] A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer [J].

Kawazoe, Akihito ;

Shitara, Kohei ;

Fukuoka, Shota ;

Kuboki, Yasutoshi ;

Bando, Hideaki ;

Okamoto, Wataru ;

Kojima, Takashi ;

Fuse, Nozomu ;

Yamanaka, Takeharu ;

Doi, Toshihiko ;

Ohtsu, Atsushi ;

Yoshino, Takayuki .

BMC CANCER, 2015, 15

[8] KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer [J].

Modest, D. P. ;

Camaj, P. ;

Heinemann, V. ;

Schwarz, B. ;

Jung, A. ;

Laubender, R. P. ;

Gamba, S. ;

Haertl, C. ;

Stintzing, S. ;

Primo, S. ;

Bruns, C. J. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) :953-961

[9] BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications [J].

Oikonomou, Eftychia ;

Koustas, Evangelos ;

Goulielmaki, Maria ;

Pintzas, Alexander .

ONCOTARGET, 2014, 5 (23) :11752-11777

[10] KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression [J].

Oliveira, C. ;

Velho, S. ;

Moutinho, C. ;

Ferreira, A. ;

Preto, A. ;

Domingo, E. ;

Capelinha, A. F. ;

Duval, A. ;

Hamelin, R. ;

Machado, J. C. ;

Schwartz, S., Jr. ;

Carneiro, F. ;

Seruca, R. .

ONCOGENE, 2007, 26 (01) :158-163

← 1 2 →